The company anticipates normalizing patient treatment metrics by Q1 2026 and the introduction of a permanent product J-code by CMS in January 2026 is expected to support revenue growth. Abeona is strategically expanding its qualified treatment center network, with three activated centers including Children's Hospital Colorado. The company projects profitability in the first half of 2026.
Cyborg Score Rationale
The company has $207.5 million in cash as of September 30, 2025, providing significant financial flexibility for ZEVASKYN commercial launch. Abeona is projected to achieve approximately $32 million in revenue for 2025, with significant expected growth to $130.4 million by 2026. However, as a clinical-to-commercial stage company, execution risk remains.
Top Insights
First commercial patient treatment with FDA-approved ZEVASKYN announced in December 2025.
Consensus analyst rating is Strong Buy with a 2026 price target of $20, representing significant upside from current trading levels.
Management reports doubling of identified patients, indicating growing market awareness.
Company sold $152 million in Priority Review Voucher (PRV) to bolster cash reserves, strategic de-risking move.
Named Competitors
Gene therapies for rare genetic diseases — AAV-based gene therapy platform for multiple indications
Cell and gene therapies — Gene therapy developer for severe genetic diseases
Gene editing for rare diseases — Gene editing platform for multiple rare disease indications
Recent Developments
(December 2025) First commercial patient treatment with ZEVASKYN completed
(January 2026) Permanent CMS J-code implementation for ZEVASKYN reimbursement
(November 2025) Q3 2025 earnings reported with narrowed net loss and positive commercial momentum
(June 2025) Added to Russell 2000 Index
Open the full interactive Abeona Therapeutics Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.